| Not Yet Recruiting | Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout NCT06887452 | VA Office of Research and Development | N/A |
| Not Yet Recruiting | A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants NCT07535034 | Crystalys Therapeutics | Phase 2 |
| Not Yet Recruiting | The Remote Monitoring of Gout Feasibility Study in Primary Care NCT07490522 | Diakonhjemmet Hospital | N/A |
| Recruiting | Tigulixostat (IBI128) vs Febuxostat in Gout NCT07414394 | Innovent Biologics Technology Limited (Shanghai R&D Center) | Phase 3 |
| Recruiting | Drug-Drug Interaction Study of ABP-671 in Gout Patients NCT07367971 | Atom Therapeutics Co., Ltd | Phase 1 |
| Recruiting | A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing NCT07280156 | Protalix | Phase 2 |
| Recruiting | Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares NCT07346079 | Massachusetts General Hospital | Phase 4 |
| Not Yet Recruiting | Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT NCT07326839 | XueMei Guo | N/A |
| Recruiting | Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients NCT07116746 | Arthrosi Therapeutics | Phase 2 |
| Recruiting | A Study of Dotinurad Versus Allopurinol in Participants With Gout NCT07089875 | Crystalys Therapeutics | Phase 3 |
| Not Yet Recruiting | Using Gout Buddy to Enhance Gout Management NCT07004231 | SingHealth Polyclinics | N/A |
| Recruiting | Tight Control of Gouty Arthritis Compared to Usual Care NCT05507723 | University of Edinburgh | N/A |
| Recruiting | Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gout NCT06995339 | Mostafa Bahaa | Phase 2 |
| Recruiting | Metformin in Safety and Efficacy in Gouty Patients NCT06924658 | Mostafa Bahaa | Phase 2 |
| Recruiting | Dose Response of Exercise for Arthritis Management NCT06880653 | University of South Carolina | N/A |
| Active Not Recruiting | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) NCT06846515 | Arthrosi Therapeutics | Phase 3 |
| Completed | UR+AIMS Gout Wearable Skin Uric Acid Monitor Study NCT06187519 | University of California, Los Angeles | N/A |
| Recruiting | The Orienting Study NCT07504146 | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | — |
| Not Yet Recruiting | The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More NCT06622603 | Seoul National University Hospital | Phase 4 |
| Recruiting | Time Required to Dissolve Urate Deposits NCT06669000 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects NCT06501534 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Active Not Recruiting | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) NCT06439602 | Arthrosi Therapeutics | Phase 3 |
| Recruiting | Improving Gout Care After an ED Visit NCT06534554 | University of Alabama at Birmingham | N/A |
| Active Not Recruiting | PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function NCT06729853 | Shanton Pharma Pte. Ltd. | Phase 1 / Phase 2 |
| Terminated | Extension Study of ABP-671 in Participants With Gout NCT06276556 | Atom Therapeutics Co., Ltd | Phase 2 / Phase 3 |
| Completed | A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared W NCT06229145 | Amgen | Phase 4 |
| Completed | The Remote Monitoring of Gout Feasibility Study NCT06211322 | Diakonhjemmet Hospital | N/A |
| Recruiting | Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout NCT04875702 | Massachusetts General Hospital | Phase 4 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy V NCT06258213 | Atom Therapeutics Co., Ltd | Phase 1 |
| Completed | Prevalence of Musculoskeletal Complaints in Nursing Home Residents NCT06235710 | Maastricht University Medical Center | — |
| Recruiting | Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia NCT06629376 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Completed | Effect of Tigulixostat on the Pharmacokinetics of Theophylline NCT06189404 | LG Chem | Phase 1 |
| Completed | Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia NCT06056570 | Urica Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout NCT05818085 | Atom Therapeutics Co., Ltd | Phase 2 / Phase 3 |
| Recruiting | Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration NCT05109936 | University Hospital, Rouen | Phase 3 |
| Completed | A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering NCT05936281 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Synd NCT05927688 | University Hospital, Strasbourg, France | — |
| Completed | SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects NCT06678581 | Shanton Pharma Co., Ltd. | Phase 1 |
| Active Not Recruiting | Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout NCT05665699 | InventisBio Co., Ltd | Phase 2 |
| Completed | Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients NCT05586971 | LG Chem | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevat NCT05745727 | Protalix | Phase 1 |
| Active Not Recruiting | A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients NCT05815901 | JW Pharmaceutical | Phase 3 |
| Completed | Genetic of Chronic Kidney Disease and Gout in New Caledonia NCT05607797 | Lille Catholic University | N/A |
| Recruiting | A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. NCT06298071 | Shanghai Institute Of Biological Products | Phase 1 |
| Recruiting | Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare NCT05658575 | Olatec Therapeutics LLC | Phase 2 / Phase 3 |
| Unknown | Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) NCT05473325 | Willows Health | — |
| Active Not Recruiting | Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. NCT05690204 | Shanton Pharma Pte. Ltd. | Phase 2 |
| Completed | Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients NCT05586958 | LG Chem | Phase 3 |
| Unknown | An Innovative Chinese Herbal Formula for the Treatment of Gout NCT05499312 | Chinese University of Hong Kong | Phase 2 |
| Terminated | Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney NCT04987294 | Allena Pharmaceuticals | Phase 2 |
| Recruiting | Prevalence of Abnormalities in Ultrasonography of Joint and Tendons in Patients With Gout NCT05546593 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Topha NCT05253833 | Arthrosi Therapeutics | Phase 2 |
| Completed | To Evaluate the Influence of (LUA Probiotics) on Uric Acid NCT06969469 | Grape King Bio Ltd. | — |
| Unknown | Effect of Aquatic Exercise and Traditional Physical Therapy on Gout in Hypertensive Menopausal Women With Hype NCT05454423 | Merit University | N/A |
| Suspended | Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transpla NCT04844814 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Phone-Based Based Walk With Ease Program for Adults With Arthritis NCT05289544 | University of South Carolina | N/A |
| Terminated | A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout NCT05256810 | Alnylam Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Delivery of Enhance Fitness Trial NCT05275348 | University of Washington | N/A |
| Completed | Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets NCT05168683 | Allena Pharmaceuticals | Phase 1 |
| Completed | A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout NCT05007392 | Eisai Co., Ltd. | Phase 3 |
| Active Not Recruiting | Treat-to-target by Email During Urate-lowering Therapy in Gout NCT04733079 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing NCT05127772 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients NCT05119686 | Arthrosi Therapeutics | Phase 2 |
| Unknown | To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout NCT05324423 | The Affiliated Hospital of Qingdao University | Phase 1 |
| Completed | Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Femal NCT04966325 | LG Chem | EARLY_Phase 1 |
| Completed | Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial NCT04776161 | Brigham and Women's Hospital | N/A |
| Completed | Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults NCT04886050 | LG Chem | Phase 1 |
| Completed | An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) NCT04987242 | Allena Pharmaceuticals | Phase 2 |
| Completed | Acute Effects of Tart Cherry on Uric Acid and Biomarkers of CVD Risk in Healthy Individuals NCT04960527 | Sheffield Hallam University | N/A |
| Unknown | Research and Development of a New Technology for Detection of Abnormal Excretion of Intestinal Uric Acid Invol NCT04953533 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of S NCT04956432 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Active Not Recruiting | Gout in the ED and Improving Research Participation NCT04075903 | University of Alabama at Birmingham | N/A |
| Completed | Tahiti-families: Polynesian Families of Gout Patients NCT04900090 | Lille Catholic University | N/A |
| Unknown | Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmaph NCT04897113 | National Medical Research Center for Rehabilitation and Balneology | N/A |
| Completed | Epidemiology of Gout in French Polynesia NCT04812886 | Lille Catholic University | N/A |
| Completed | Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) NCT04829435 | Allena Pharmaceuticals | Phase 1 |
| Unknown | Treatment of Refractory Gout With ACTH or Methylprednisolone NCT04808856 | Shanghai 10th People's Hospital | N/A |
| Completed | Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C) NCT04938024 | University of Minnesota | N/A |
| Recruiting | CRYSTALILLE Cohort: Getting the Whole Picture of Crystal-related Arthropathies NCT04695028 | Lille Catholic University | — |
| Terminated | COVID-19 Vaccination in Rheumatic Disease Patients NCT04839315 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol NCT04746989 | Brigham and Women's Hospital | — |
| Withdrawn | Post-Authorisation Safety Study of Lesinurad NCT04072471 | AstraZeneca | — |
| Terminated | Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout NCT04697602 | National Taiwan University Hospital | N/A |
| Completed | A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia NCT04638543 | Atom Therapeutics Co., Ltd | Phase 2 |
| Withdrawn | Urica Cor Intervention (URICORI) Trial NCT04459936 | Torkell Ellingsen | N/A |
| Unknown | Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk NCT05309057 | University of Toronto | — |
| Unknown | The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study NCT04213534 | Peking University Third Hospital | — |
| Completed | Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in NCT04511702 | Amgen | Phase 4 |
| Completed | Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information NCT04853160 | Takeda | — |
| Completed | Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects NCT04303039 | Atom Therapeutics Co., Ltd | Phase 1 |
| Withdrawn | A Pilot Study to Explore the Role of Gut Flora in Gout NCT04224662 | ProgenaBiome | — |
| Completed | Mass Balance Study of [14C]LC350189 in Healthy Volunteers NCT04070846 | LG Chem | Phase 1 |
| Completed | Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) NCT04130204 | Dyve Biosciences, Inc. | Phase 2 |
| Active Not Recruiting | Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout NCT04125459 | Attune Health Research, Inc. | — |
| Completed | The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults NCT04139824 | LG Chem | Phase 1 |
| Completed | A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia NCT03934099 | LG Chem | Phase 2 |
| Completed | Renal PK Study of LC350189 NCT04066712 | LG Chem | Phase 1 |
| Completed | The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject NCT04040907 | Evopoint Biosciences Inc. | Phase 1 |
| Completed | The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. NCT03927677 | LG Chem | Phase 1 |
| Completed | Knowledge, Attitude and Practice Regarding Diagnosis and Management of Gout Among Clinicians in Nepal NCT04519021 | National Center for Rheumatic Diseases, Nepal | — |
| Unknown | A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunte NCT04047394 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 NCT04060173 | Atom Therapeutics Co., Ltd | Phase 1 |
| Completed | A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout NCT04052932 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Suspended | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease NCT04031469 | ProgenaBiome | — |
| Completed | Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout NCT03994731 | Amgen | Phase 4 |
| Completed | Gout Self-Monitoring Aiming to Reach Target NCT03274063 | University of Edinburgh | N/A |
| Completed | A Nurse Led Patient Management Programme to Improve Outcomes in Gout NCT03345186 | University Hospital, Basel, Switzerland | N/A |
| Completed | Pharmacokinetics and Pharmacodynamics of Anthocyanins NCT03650140 | Rutgers, The State University of New Jersey | N/A |
| Completed | Study of of URC102 to Assess the Efficacy and Safety in Gout Patients NCT04804111 | JW Pharmaceutical | Phase 2 |
| Completed | Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynami NCT04040816 | Shanton Pharma Co., Ltd. | Phase 2 |
| Unknown | Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Tri NCT04199325 | The Affiliated Hospital of Inner Mongolia Medical University | N/A |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjec NCT03906006 | Atom Therapeutics Co., Ltd | Phase 1 |
| Completed | Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout NCT03635957 | Amgen | Phase 4 |
| Completed | The Diet Gout Trial NCT03569020 | Johns Hopkins University | N/A |
| Unknown | The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients NCT03601260 | Hillel Yaffe Medical Center | N/A |
| Completed | Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis NCT03416543 | University Hospital, Tours | — |
| Completed | Evidence-based Laboratory Test Order Sets in Primary Care NCT02950142 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Unknown | The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Go NCT03306758 | Shanghai Zhongshan Hospital | N/A |
| Unknown | The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) NCT03336203 | Medical Practice Prof D. Ivanov | Phase 4 |
| Unknown | A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. NCT03388515 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 1 |
| Completed | D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers NCT03291782 | InventisBio Co., Ltd | Phase 1 |
| Completed | Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. NCT03272425 | Ardea Biosciences, Inc. | Phase 1 |
| Completed | Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Depos NCT03162341 | Lille Catholic University | N/A |
| Terminated | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairmen NCT03226899 | Ironwood Pharmaceuticals, Inc. | Phase 4 |
| Completed | Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level NCT03211403 | Atridia Pty Ltd. | Phase 1 |
| Completed | SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO2 Study NCT02741700 | VA Office of Research and Development | N/A |
| Completed | CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat NCT02579096 | VA Office of Research and Development | Phase 4 |
| Completed | The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout NCT03131583 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions NCT02903446 | University of Alabama at Birmingham | Phase 2 |
| Unknown | Descriptive Analysis of Dual-energy Computed Tomography Exams of Adult Patients With Gout NCT05065606 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Single Dose Study of SHR4640 in Healthy Male Volunteers NCT03015948 | Atridia Pty Ltd. | Phase 1 |
| Completed | Novel Methods for Ascertainment of Gout Flares -A Pilot Study NCT02855437 | University of Alabama at Birmingham | N/A |
| Unknown | Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration NCT03038386 | Meander Medical Center | N/A |
| Completed | Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility NCT02578394 | Mid and South Essex NHS Foundation Trust | Phase 2 / Phase 3 |
| Completed | Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Level NCT02648269 | Selecta Biosciences, Inc. | Phase 1 |
| Completed | Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect NCT02598596 | Ampel BioSolutions, LLC | Phase 2 |
| Completed | RDEA3170 PK/PD Study NCT02608710 | Ardea Biosciences, Inc. | Phase 1 |
| Completed | Study of URC102 to Assess the Safety and Efficacy in Gout Patients NCT02557126 | JW Pharmaceutical | Phase 2 |
| Unknown | Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases NCT02702375 | University of Toronto | — |
| Completed | Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With NCT02500641 | Menarini International Operations Luxembourg SA | Phase 4 |
| Completed | Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects NCT02498652 | Ardea Biosciences, Inc. | Phase 2 |
| Completed | Prospective Analgesic Compound Efficacy (PACE) Study NCT02403687 | Express Specialty Pharmacy | — |
| Unknown | Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors NCT02716870 | University of Toronto | — |
| Completed | Optimal Administration of Allopurinol in Dialysis Patients NCT02477488 | Maisonneuve-Rosemont Hospital | Phase 4 |
| Terminated | Pharmacogenetics of SGLT2 Inhibitors NCT02462421 | University of Maryland, Baltimore | Phase 4 |
| Completed | Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels NCT02464605 | Selecta Biosciences, Inc. | Phase 1 |
| Completed | Elastography as Gouty Arthropathy Outcome (EGO) NCT02471261 | Arthritis & Rheumatism Associates, P.C. | — |
| Unknown | Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Dis NCT03214263 | Rigshospitalet, Denmark | — |
| Completed | DECT Study in Allopurinol-Treated Gout Patients NCT02393560 | Ardea Biosciences, Inc. | — |
| Unknown | PatientSpot Formerly Known as ArthritisPower NCT03840928 | Global Healthy Living Foundation | — |
| Completed | Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout NCT02330796 | Revive Therapeutics, Ltd. | Phase 2 |
| Completed | Food Effect Study of Febuxostat XR in Healthy Participants NCT02374164 | Takeda | Phase 1 |
| Completed | A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout NCT02287818 | TWi Biotechnology, Inc. | Phase 2 |
| Completed | RDEA3170 and Allopurinol Combination Study in Gout Subjects NCT02279641 | Ardea Biosciences, Inc. | Phase 1 |
| Completed | RDEA3170 Bioavailability Study NCT02336594 | Ardea Biosciences, Inc. | Phase 1 |
| Completed | RDEA3170 and Febuxostat Combination Study in Gout Subjects NCT02246673 | Ardea Biosciences, Inc. | Phase 2 |
| Completed | Mild, Moderate and Severe Renal Impairment Study NCT02219516 | Ardea Biosciences, Inc. | Phase 1 |
| Completed | Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients W NCT02252835 | Gilead Sciences | Phase 2 |
| Completed | Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients NCT02290210 | JW Pharmaceutical | Phase 2 |
| Terminated | Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects. NCT02187029 | Pfizer | Phase 1 |
| Unknown | Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk NCT02702479 | University of Toronto | — |
| Completed | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderat NCT02128490 | Takeda | Phase 2 |
| Completed | Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout NCT02139046 | Takeda | Phase 3 |
| Completed | Effects of Fasting on Self Efficacy NCT02113111 | Universität Duisburg-Essen | — |
| Unknown | Rheumatology Informatics System for Effectiveness NCT02230943 | American College of Rheumatology | — |
| Completed | Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Pa NCT02063997 | Gilead Sciences | Phase 2 |
| Completed | Apolipoprotein CIII Reduction Via Colchicine NCT02083510 | Scripps Translational Science Institute | EARLY_Phase 1 |
| Completed | Colchicine Or Naproxen Treatment for ACute gouT NCT01994226 | Keele University | Phase 4 |
| Completed | RDEA3170 Monotherapy in Subjects With Gout NCT01927198 | Ardea Biosciences, Inc. | Phase 2 |
| Completed | Single and Multiple Dose Study in Japanese Subjects NCT01872832 | Ardea Biosciences, Inc. | Phase 1 |
| Completed | NSAID Drug Interaction Study NCT01884272 | Ardea Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Meta-Analyses of the Effect of Plant Protein Versus Animal Protein on Cardiometabolic Risk NCT02037321 | John Sievenpiper | — |
| Completed | Lesinurad and Febuxostat Combination Extension Study in Gout NCT01808144 | Ardea Biosciences, Inc. | Phase 3 |
| Unknown | The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syn NCT01818505 | National Taiwan University Hospital | — |
| Completed | Arthritis Research UK Gout Treatment Trial - Phase 2 NCT01477346 | University of Nottingham | N/A |
| Completed | Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial NCT01881919 | University of Leeds | EARLY_Phase 1 |
| Completed | Lesinurad and Allopurinol Combination Extension Study in Gout NCT01808131 | Ardea Biosciences, Inc. | Phase 3 |
| Completed | Virtual Gout Clinic NCT02790463 | University of Alabama at Birmingham | N/A |
| Completed | Impact of Unapproved Drug Initiative on Colchicine Use NCT02000232 | Stanford University | — |
| Completed | Purine Metabolism Enzyme SNP to Uric Acid Production NCT01830725 | Keesler Air Force Base Medical Center | — |
| Completed | Single and Multiple Dose Study in Japanese NCT01744379 | Ardea Biosciences, Inc. | Phase 1 |
| Completed | Open-Label Lesinurad Monotherapy Extension Study in Gout NCT01650246 | Ardea Biosciences, Inc. | Phase 3 |
| Unknown | Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments NCT01642706 | University Hospital, Montpellier | — |
| Unknown | Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease NCT01608620 | John Sievenpiper | — |
| Completed | Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome NCT01654276 | University of Texas Southwestern Medical Center | Phase 4 |
| Completed | Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease NCT04952896 | Peking University Third Hospital | — |
| Completed | Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Voluntee NCT01563432 | SK Chemicals Co., Ltd. | Phase 1 |
| Completed | Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors NCT01508702 | Ardea Biosciences, Inc. | Phase 3 |
| Unknown | Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout NCT01519687 | Pharmos | Phase 2 |
| Completed | Combining Lesinurad With Allopurinol in Inadequate Responders NCT01510158 | Ardea Biosciences, Inc. | Phase 3 |
| Unknown | Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gou NCT05006001 | En Chu Kong Hospital | — |
| Completed | Combining Lesinurad With Allopurinol in Inadequate Responders NCT01493531 | Ardea Biosciences, Inc. | Phase 3 |
| Terminated | Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares NCT01459796 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure NCT01472692 | University of California, San Diego | Phase 4 |
| Completed | A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to NCT01407874 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Pati NCT01416402 | Gilead Sciences | Phase 2 |
| Completed | Safety and Efficacy of Oral Febuxostat in Subjects With Gout NCT02082769 | Xijing Hospital | Phase 3 |
| Completed | Allopurinol Outcome Study NCT01391325 | Ardea Biosciences, Inc. | Phase 4 |
| Completed | Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals NCT01363869 | Chiang Mai University | N/A |
| Completed | Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients NCT01399008 | Gilead Sciences | Phase 2 |
| Completed | Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 NCT01361646 | LG Life Sciences | Phase 1 |
| Completed | Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout NCT01336686 | Gilead Sciences | Phase 2 |
| Completed | Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of Life NCT01549210 | Italian Society for Rheumatology | — |
| Completed | A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout NCT01736514 | Astellas Pharma Taiwan, Inc. | Phase 3 |
| Completed | Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol NCT01265264 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | Hereditary Tubulointerstitial Nephritis NCT01312727 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management NCT01151709 | University of Massachusetts, Worcester | — |
| Completed | Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subje NCT01129648 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. NCT01112982 | University of South Florida | Phase 4 |
| Completed | Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia NCT01052987 | Nuon Therapeutics, Inc. | Phase 2 |
| Terminated | The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study NCT01701622 | University of Mississippi Medical Center | N/A |
| Unknown | Safety and Efficacy Study of Intramuscular Uricase-PEG 20 NCT01038947 | EnzymeRx | Phase 1 |
| Completed | Allopurinol Combination Study NCT01001338 | Ardea Biosciences, Inc. | Phase 2 |
| Unknown | Safety and Efficacy Study of Intravenous Uricase-PEG 20 NCT01021241 | EnzymeRx | Phase 1 |
| Completed | Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia NCT00995618 | Nuon Therapeutics, Inc. | Phase 2 |
| Completed | Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout NCT00985127 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) NCT00958438 | Regeneron Pharmaceuticals | Phase 3 |
| Unknown | Meta-analyses of Fructose and Cardiometabolic Risk NCT01363791 | John Sievenpiper | — |
| Completed | Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) NCT00856206 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM NCT01529099 | DePuy International | Phase 4 |
| Completed | A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allop NCT00819585 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Uric Acid Study in Healthy Male Volunteers NCT00738842 | AstraZeneca | Phase 1 |
| Withdrawn | CLinical Prediction Rule Score in Veterans NCT01418781 | jasvinder singh | — |
| Completed | Does Allopurinol Prolong a Treated, Acute Gout Flare? NCT01988402 | 59th Medical Wing | Phase 4 |
| Completed | Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares NCT00610363 | Regeneron Pharmaceuticals | Phase 2 |
| Completed | MRI and Ultrasound Findings in Patients With Gout and Normal Plain Radiographs NCT00584311 | University of South Florida | N/A |
| Completed | MPC-004 for the Treatment of an Acute Gout Flare NCT00506883 | Takeda | Phase 3 |
| Completed | Efficacy and Safety of Oral Febuxostat in Participants With Gout NCT00430248 | Takeda | Phase 3 |
| Completed | Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptoma NCT01356498 | Savient Pharmaceuticals | Phase 3 |
| Completed | Phase III Trial of Febuxostat in Korea Gout Patients NCT00821392 | SK Chemicals Co., Ltd. | Phase 3 |
| Completed | Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663- NCT01685424 | Organon and Co | — |
| Completed | Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout NCT00325195 | Savient Pharmaceuticals | Phase 3 |
| Completed | Vegetarian Diet and Chronic Degenerative Diseases NCT03470584 | Dalin Tzu Chi General Hospital | — |
| Completed | Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout NCT00111657 | John Sundy | Phase 2 |
| Completed | A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy NCT00080210 | Savient Pharmaceuticals | Phase 2 |
| Completed | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 NCT00175019 | Takeda | Phase 3 |
| Completed | Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. NCT00174915 | Takeda | Phase 3 |
| Completed | Validation Study of Physical Measurement of Tophi NCT00175006 | Takeda | — |
| Completed | Febuxostat Versus Allopurinol Control Trial in Subjects With Gout NCT00102440 | Takeda | Phase 3 |
| Completed | Magnetic Resonance Imaging in Subjects With Gouty Tophi NCT00174954 | Takeda | — |
| Completed | Long-Term Safety of Febuxostat in Subjects With Gout. NCT00174941 | Takeda | Phase 2 |
| Completed | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout NCT00174967 | Takeda | Phase 2 |
| Completed | Exploring the Comorbidity Between Mental Disorders and General Medical Conditions NCT03847753 | University of Aarhus | — |
| Completed | Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout NCT01310673 | White River Junction Veterans Affairs Medical Center | Phase 4 |
| Withdrawn | Allopurinol in Acute Gout NCT01775098 | Université de Sherbrooke | N/A |